药明康德瑞士库威基地获EcoVadis最新企业社会责任评级银牌认证 | Bilingual News

药明康德 · 公众号 · 药品 · 2024-11-15 08:10

正文

▎药明康德

药明康德近日宣布，其位于瑞士库威的生产基地获得全球企业社会责任评级专业机构EcoVadis银牌认证，这也体现了药明康德将环境、社会及管治（ESG）融入公司战略和运营的坚定信念。

作为全球知名的企业社会责任评级机构，EcoVadis为各行业提供重要的国际企业社会责任标准，旨在推动全球供应链的可持续发展，增强行业竞争力，促进建立更好的全球实践案例并持续改进。EcoVadis针对企业在环境、劳工与人权、商业道德和可持续采购四大核心领域的表现进行评估，药明康德库威生产基地凭借出色表现，在所有参与评级的公司中排名前9%，进一步彰显了公司的社会责任和对可持续发展的坚定承诺。

库威生产基地是药明康德CRDMO业务平台的重要组成部分，拥有全球领先的片剂和胶囊临床用药和商业化生产及包装能力。该基地在设计之初就采用了行业领先的能效和环境标准，适合未来的可持续发展。同时，库威生产基地成功获得了ISO 14001（环境管理体系）和ISO 45001（职业健康安全管理体系）认证，旨在以先进的环境、健康和安全管理体系，推动公司的可持续发展。

作为创新的赋能者、客户信赖的合作伙伴以及全球健康产业的贡献者，药明康德将ESG理念融入公司战略和运营的方方面面。2024年，药明康德在标普全球企业可持续发展评估（S&P Global Corporate Sustainability Assessment，CSA）中获得行业最高分，位列全球“生命科学工具与服务”领域第一；同年，药明康德连续第四年被MSCI评为ESG AA级；2023和2024年，公司连续两年入选标普全球可持续发展年鉴和富时罗素社会责任指数系列，并同时获评Sustainalytics“行业最高评级”和“区域最高评级”企业；2024年，公司加入了“联合国全球契约组织”（United Nations Global Compact，UNGC），承诺支持全球契约十项原则；2023年，公司加入“科学碳目标倡议”（Science Based Targets initiative，SBTi）以减少碳排放。药明康德出色的ESG表现也受到了CDP等全球ESG评级机构的高度认可。

关于药明康德

药明康德（股票代码：603259.SH/2359.HK）为全球医药及生命科学行业提供一体化、端到端的新药研发和生产服务，在亚洲、欧洲、北美等地均设有运营基地。药明康德通过独特的“CRDMO”和“CTDMO”业务模式，不断降低研发门槛，助力客户提升研发效率，为患者带来更多突破性的治疗方案，服务范围涵盖化学药研发和生产、生物学研究、临床前测试和临床试验研发、精准医疗研发、测试和生产等领域。2024年，药明康德连续第四年被MSCI评为ESG（环境、社会及管治）AA级。目前，公司的赋能平台正承载着来自全球30多个国家的6,000多家合作伙伴的研发创新项目，致力于将更多新药、好药带给全球病患，早日实现“让天下没有难做的药，难治的病”的愿景。

WuXi AppTec’s Couvet Site Receives EcoVadis 2024 Silver Medal Rating

Couvet, Switzerland - November 14, 2024 - WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, is proud to announce that its facility in Couvet, Switzerland, has received a silver medal in the 2024 business sustainability ratings by EcoVadis, a leading business sustainability rating provider. This recognition highlights WuXi AppTec’s steadfast commitment to integrating Environmental, Social, and Governance (ESG) priorities into its strategy and operations.

EcoVadis provides benchmarks for rated companies in their industry to drive global supply chain sustainability and encourage industry-wide competence to achieve better global practice and continuous improvement. The ratings assess corporate performance across four core areas: Environment, Labor & Human Rights, Ethics, and Sustainable Procurement. With an impressive score, WuXi AppTec’s Couvet site ranks in the top 9% of all rated companies, showcasing its commitment to sustainable business practices.

As a state-of-the-art pharmaceutical manufacturing facility, the Couvet site plays a vital role in WuXi AppTec’s CRDMO business model by providing both clinical and commercial scale manufacturing capabilities for oral solid dosage forms. The facility was designed with industry-leading energy efficiency and environmental standards and was built to accommodate future sustainable growth.

In addition to receiving the EcoVadis silver medal, the site was also recertified for ISO 14001 & ISO 45001 accreditations to the advanced environmental, health and safety management systems that enhance its sustainability performance.

As an enabler of innovation, a trusted partner, and a contributor to the global pharmaceutical and life sciences industry, WuXi AppTec integrates ESG priorities in all aspects of its global business operations. In 2024, WuXi AppTec ranked #1 in Global Life Sciences Tools & Services Industry in S&P Global Corporate Sustainability Assessment and received an AA ESG rating from MSCI for the fourth consecutive year. The company was also named to the S&P Global Sustainability Yearbook and the FTSE4Good Index Series for the second consecutive year in both 2023 and 2024, and was recognized as an Industry and Regional “Top-Rated” company by Sustainalytics. WuXi AppTec’s outstanding ESG performance has been widely acknowledged by major global ESG rating agencies, including CDP.

Additionally, WuXi AppTec joined the United Nations Global Compact (UNGC) in 2024 in support of its ten sustainability principles, and joined the Science Based Targets initiative (SBTi) to reduce carbon emissions in 2023.

About WuXi AppTec

As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development, and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, advanced therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the fourth consecutive year in 2024, and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated."

分享，点赞，在看，聚焦全球生物医药健康创新